Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06065059 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
A Phase 1 study, sponsored by Tango Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06065059 is a Phase 1 study that was terminated before completion, run by Tango Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT06065059, a Phase 1 study, was terminated before completion, sponsored by Tango Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question\[s\] it aims to answer are: * to evaluate the safety and tolerability of single agent and combination therapy * to determine the recommended dose for Phase 2 of single agent and combination therapy * to determine the pharmacokinetics of TNG348 as a single agent and in combination therapy * to evaluate the initial antineoplastic activity as a single agent and in combination therapy Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Interventions
- DRUG Olaparib
- DRUG TNG348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06065059
The ClinicalTrials.gov registry entry for NCT06065059 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tango Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT06065059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06065059 about?
NCT06065059 is a clinical study titled "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors". The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors. The main question\[s\] it aims to answer are: * to evaluate the safety and toler...
What is the current status of trial NCT06065059?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-12-08. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT06065059?
The interventions under investigation include: Olaparib (DRUG), TNG348 (DRUG).
Who is sponsoring clinical trial NCT06065059?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.